Sutro Biopharma

Yahoo Finance • 18 days ago

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day

- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - Investor webcast today at 7:00AM PT / 10:00... Full story

Yahoo Finance • 23 days ago

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – – Company presented new preclinical data at... Full story

Yahoo Finance • 24 days ago

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced th... Full story

Yahoo Finance • 27 days ago

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it... Full story

Yahoo Finance • 2 months ago

Sutro Biopharma announces restructuring to extend cash runway

* Sutro Biopharma (NASDAQ:STRO [https://seekingalpha.com/symbol/STRO]) announced [https://seekingalpha.com/pr/20248029-sutro-biopharma-announces-operational-restructuring-intended-to-extend-cash-runway-through] on Monday an organizationa... Full story

Yahoo Finance • 2 months ago

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format an... Full story

Yahoo Finance • 2 months ago

WES Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Western Midstream Partners LP (Symbol: WES) crossed below their 200 day moving average of $26.72, changing hands as low as $26.51 per share. Western Midstream Partners LP shares are currently trading off a... Full story

Yahoo Finance • 4 months ago

Sutro Biopharma GAAP EPS of -$0.14, revenue of $63.7M

* Sutro Biopharma press release [https://seekingalpha.com/pr/20194321-sutro-biopharma-reports-second-quarter-2025-financial-results-and-business-highlights] (NASDAQ:STRO [https://seekingalpha.com/symbol/STRO]): Q2 GAAP EPS of -$0.14. *... Full story

Yahoo Finance • 4 months ago

Sutro Biopharma Inc (NASDAQ:STRO) Reports Q2 2025 Revenue Beat and Narrower Losses, Shares Rise in After-Hours Trading

SUTRO BIOPHARMA INC (NASDAQ:STRO [https://www.chartmill.com/stock/quote/STRO]) reported its second-quarter 2025 financial results, delivering a significant revenue beat while narrowing its losses compared to analyst expectations. The compa... Full story

Yahoo Finance • 4 months ago

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research... Full story

Yahoo Finance • 5 months ago

Earnings call transcript: Strongpoint Q2 2025 sees positive EBITDA, 18% revenue growth

Strongpoint ASA reported strong financial results for the second quarter of 2025, showcasing significant improvements in revenue and profitability. The company achieved an 18% year-over-year revenue increase, reaching NOK 350 million. EBIT... Full story

Yahoo Finance • 5 months ago

StrongPoint Q2 2025 slides: Revenue up 18%, EBITDA improves amid retail tech expansion

Introduction & Market Context StrongPoint ASA (OB:STRO) presented its second quarter 2025 results on July 11, showing continued revenue growth and improved profitability as the retail technology provider expands its footprint across Europ... Full story

Yahoo Finance • 5 months ago

Piper Sandler upgrades Sutro Biopharma stock rating on pipeline progress

Piper Sandler upgraded Sutro Biopharma (NASDAQ:STRO) from Neutral to Overweight on Monday, setting a price target of $2.00 for the biopharmaceutical company focused on antibody-drug conjugates (ADCs). According to InvestingPro data, the... Full story

Yahoo Finance • 9 months ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced e... Full story

Yahoo Finance • 9 months ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of Dec... Full story

Yahoo Finance • 9 months ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next... Full story

Yahoo Finance • 9 months ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), tod... Full story

Yahoo Finance • 2 years ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Sutro Biopharma, Inc. SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug co... Full story

Yahoo Finance • 2 years ago

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcy... Full story

Yahoo Finance • 2 years ago

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), toda... Full story